How Putnam’s CEO Matt Riordan Is Accelerating Cancer Therapy Adoption | ASCO 2025 Highlights

1 Views
Published
At ASCO 2025, Matt Riordan, CEO of Putnam Associates, part of Inizio Advisory, shares expert insights on the future of cancer treatment, commercialization strategy, and accelerating the adoption of next-gen therapies across clinical settings.

???? Highlights

✅ Key challenge: ensuring adoption across both academic and community oncology
✅ Faster clinician and patient education = faster uptake of breakthrough drugs
✅ Real-world strategy behind the launch of the first CAR-T therapy
✅ AI in oncology: overhyped or underutilized? Why human judgment still matters
✅ Aligning medical, commercial, and access teams around a unified strategy
✅ Inizio’s integrated approach: turning strategy into action across the lifecycle
✅ Why the real win is accelerating access for patients—without delay


#ASCO2025 #PutnamAssociates #InizioAdvisory #OncologyStrategy #CancerInnovation #CAR_T #RadioligandTherapy

SUBSCRIBE to get the latest #oncodaily https://www.youtube.com/@OncoDailyTV

Visit the OncoDaily Website : https://oncodaily.com
Like OncoDaily on LinkedIn: https://linkedin.com/company/oncodaily
Like OncoDaily on X (Twitter): https://x.com/oncodaily
Follow OncoDaily on Instagram: https://www.instagram.com/oncodailynews/
Follow OncoDaily on TikTok: https://www.tiktok.com/@oncodaily
Like OncoDaily on Facebook: https://www.facebook.com/oncodaily/

SUBSCRIBE to OncoDaily Newsletter: https://oncodaily.com/submit-newsletter

About OncoDaily
OncoDaily is your trusted source for the latest oncology news, expert interviews, patient stories, and cutting-edge research. Our mission is to empower the global cancer community—patients, survivors, professionals, and advocates—with timely, credible information.

Subscribe for weekly podcasts, expert conversations, and updates on groundbreaking cancer research.

???? New videos every day!
???? Visit us at https://oncodaily.com/
Category
Oncology
Be the first to comment